Tiburio is advancing a pipeline of clinic ready assets.
Tiburio’s clinical stage pipeline is based on dopamine-somatostatin chimeric molecules for the treatment of severe endocrine disorders. Dopamine-somatostatin chimeric compounds have evolved as a therapeutic drug class with the potential to have broad application across various endocrine diseases [1]. Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that result in enhanced activity, offering new potential for a variety of diseases with unmet need [2,3].
| Compound | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| TBR-760 For treatment of NFPA. |
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
| TBR-065 For treatment of rare endocrine disorders. |
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
References:
[1] Culler MD. (2011). “Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors.” Horm. Metab. Res.; 43: 854- 857.
[2] Tiburio, unpublished data on file.
[3] Halem H. (2016). A Novel Somatostatin-Dopamine Chimeric Compound Induces Dose‐Related Suppression of GHRH-Stimulated Growth Hormone Secretion and Increases Insulin Sensitivity in Normal Rats. Poster session presented at the ENDO 2016 meeting, San Francisco, CA.